Thalia Therapeutics PLC
0GO
Company Profile
Business description
Thalia Therapeutics PLC is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Its pipeline includes a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a) [Lp(a)], which are established risk factors for cardiovascular disease.
Contact
2 Portman Street
LondonW1H 6DU
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Is SpaceX a threat to this ASX giant?
Investors are raising concerns about the future of telecommunication connectivity in Australia.
stocks
Chart of the Week: This ASX top pick might be overlooked
ASX top pick remains cheap as investor concerns around wage costs might be overdone.
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,126.80 | 39.10 | -0.43% |
| CAC 40 | 8,424.44 | 6.35 | -0.08% |
| DAX 40 | 24,898.44 | 36.23 | -0.15% |
| Dow JONES (US) | 51,492.55 | 507.12 | -0.98% |
| FTSE 100 | 10,401.07 | 107.54 | -1.02% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,021.66 | 354.69 | -1.34% |
| Nikkei 225 | 71,053.49 | 1,151.24 | 1.65% |
| NZX 50 Index | 13,363.31 | 29.67 | -0.22% |
| S&P 500 | 7,420.10 | 91.25 | -1.21% |
| S&P/ASX 200 | 8,911.10 | 37.60 | -0.42% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |